Position in BBIO
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$7,426
New position
Shares Held
100
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Anfield Capital Management, LLC holds $4,283,063 across 7 Biotechnology names. BBIO ranks #5 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
119,451 | $3,308,792 | |
| 2 | ZNTL |
Zentalis Pharmaceuticals, Inc.
|
274,516 | $642,367 | |
| 3 | IMNM |
Immunome Inc.
|
13,647 | $298,459 | |
| 4 | HRTX |
Heron Therapeutics, Inc. /De/
|
30,000 | $24,000 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
This page
|
100 | $7,426 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3 | $1,339 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
36 | $680 |
All Filings in BBIO
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,426 | 100 | Shares | Defined | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||